$FIG

Figma stock plunged 37% in 2026 despite maintaining above-average revenue growth, raising questions about whether current levels present a buying opportunity or reflect justified concerns about AI disruption.

ARK Invest bought just three stocks last week—Figma, Arcturus Therapeutics, and 10x Genomics—signaling selective conviction in growth equities amid broader market uncertainty.

Adobe CEO Shantanu Narayen steps down after 18 years; stock falls 5% despite beating Q1 earnings with $6.4B revenue. Valuation now at 12x P/E.

Three growth stocks—Oracle, Figma, and Zscaler—trade at steep discounts with strong fundamentals, offering potential returns from $3,000 invested wisely.

SaaS stocks down 24% YTD amid valuation concerns, but companies like Figma and Axon show resilience with strong revenue growth and AI expansion despite sector weakness.

Figma rebounds on strong 41% revenue growth and positive free cash flow, but valuation concerns persist as stock remains 80% below IPO price amid profitability questions.

General Magic secures $7.2M seed funding for SMS-based AI platform automating insurance workflows. Technology reduces quote generation time from 30 minutes to under three minutes.

Ark Investment increased positions in Figma, CoreWeave, and Recursion Pharmaceuticals Friday, buying growth stocks trading below 2025 peaks based on valuation opportunities and emerging tech trends.

Large-cap stocks rallied on strong earnings and corporate actions. First Majestic Silver led with 25% gains, joined by Moderna and Global Payments on positive results.

Figma stock surged 18% after beating earnings expectations and issuing strong 2026 guidance. AI features drove user growth, signaling robust demand for the design platform.

a16z invests $465M in Navan, making it the fund's second-largest holding. The corporate spending platform has evolved beyond travel booking to offer integrated expense management and AI-powered payment solutions.